Back to search

Article

Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims Database

2022-05-19

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Importance</h4> Data on real-world effectiveness of casirivimab and imdevimab (CAS+IMD) for treatment of coronavirus 2019 (COVID-19) are limited, especially with regard to variants of concern such as Delta. <h4>Objective</h4> To assess effectiveness of CAS+IMD versus no COVID-19 antibody treatment among patients diagnosed with COVID-19 in the ambulatory setting overall and among subgroups, in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e959ad21-4461-5675-b8fe-521e16c4a0fb
DOI
10.1101/2022.05.19.22272842
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims DatabaseDOI 10.1101/2022.05.19.22272842
Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims DatabasesSemantic proximity
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity
Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective studySemantic proximity
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trialSemantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemicSemantic proximity
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron PhaseSemantic proximity
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesSemantic proximity
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platformSemantic proximity
Select a neighboring publication to make it the new centre.